Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy

BACKGROUND: In situ tumor vaccine has been gradually becoming a hot research field for its advantage of achieving personalized tumor therapy without prior antigen identification. Various in situ tumor vaccine regimens have been reported to exert considerable antitumor efficacy in preclinical and cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Zhichen, Chu, Yanhong, Xiao, Jie, Yang, Yueling, Meng, Fanyan, Wang, Xinyue, Dong, Yanbing, Zhu, Junmeng, Wu, Yirong, Qin, Lanqun, Ke, Yaohua, Liu, Baorui, Liu, Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498626/
https://www.ncbi.nlm.nih.gov/pubmed/37700338
http://dx.doi.org/10.1186/s12967-023-04504-w

Ejemplares similares

Ejemplares similares